United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [ see clinical studies (14.1).] alendronate sodium tablets are indicated for the prevention of postmenopausal osteoporosis [ see clinical studies (14.2)]. alendronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies ( 14.3)]. alendronate sodium tablets are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies ( 14.4)]. alendronate sodium tablets are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's disease of bon

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium 5 mg - fosamax is indicated for: - treatment and prevention of osteoporosis in postmenopausal women for the treatment of osteoporosis, fosamax increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (see clinical pharmacology, pharmacodynamics.) for the prevention of osteoporosis, fosamax may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. bone loss is particularly rapid in postmenopausal women younger than age 60. risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviatio

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - alendronate sodium trihydrate 91.35mg equivalent to 70 mg alendronate;   - tablet - 70 mg - active: alendronate sodium trihydrate 91.35mg equivalent to 70 mg alendronate   excipient: magnesium stearate mannitol microcrystalline cellulose - apo-alendronate is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · for the treatment of osteoporosis in men to prevent fractures. · for treatment of paget??s disease of bone in men and women.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; magnesium stearate; butylated hydroxytoluene; gelatin; medium chain triglycerides; sucrose - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.14 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sucrose; gelatin; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; butylated hydroxytoluene; povidone; medium chain triglycerides - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - alendronate sodium trihydrate, quantity: 91.35 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; mannitol; microcrystalline cellulose - treatment of osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.